Azanta is a specialty pharma company with primary focus on Oncology. Azanta's portfolio of specialty pharma products funds the development of proprietary cancer products from late stage drug development through to registration.
Azanta is dedicated to health which predominantly and historically has led us to focus our efforts on women's health care. Azanta has a string of products addressing women's needs. We constantly strive to broaden our portfolio of products to address unmet medical needs which also include focus on men'shealth.
Making available substitution medicine for drug addicts is a niche focus of Azanta's specialty pharma company. Azanta is dedicated to serve the National Health Authorities in providing treatment that improves people's quality of life on a daily basis.
Azanta is an international specialty biopharmaceutical company developing treatments for orphan oncology and women's health indications. Our lead product candidates are Nimoral and Angusta®. To support our operations and to subsidize our development of Nimoral and Angusta® and other orphan oncology and women's health care product candidates, we currently market and distribute a portfolio of specialty pharmaceuticals products pursuant to third party distribution agreements. Constantly, Azanta looks for new licensing opportunities and partners with products to supplement and broaden the products in our existing portfolio that at the same time addresses unmet treatment needs.
2016-02-25Azanta A/S files Marketing Authorisation Application for Angusta®
Hellerup, Denmark, February 25, 2016.
Azanta A/S announces that a marketing authorisa...
2015-12-14Azanta A/S Welcomes Bo Jesper Hansen as Board Member
Azanta A/S welcomes Bo Jesper Hansen as a member of the Board of Directors and David Kauffman...
2015-10-02Azanta A/S Completes DKK 46.4 million Capital Increase
Hellerup, Denmark, October 2, 2015.
Today Azanta A/S announce the successful completi...